IBDEI1PK ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,30268,2)
 ;;=^5017100
 ;;^UTILITY(U,$J,358.3,30269,0)
 ;;=O36.8125^^178^1916^6
 ;;^UTILITY(U,$J,358.3,30269,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30269,1,3,0)
 ;;=3^Decreased fetal movements, second trimester, fetus 5
 ;;^UTILITY(U,$J,358.3,30269,1,4,0)
 ;;=4^O36.8125
 ;;^UTILITY(U,$J,358.3,30269,2)
 ;;=^5017094
 ;;^UTILITY(U,$J,358.3,30270,0)
 ;;=O36.8135^^178^1916^12
 ;;^UTILITY(U,$J,358.3,30270,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30270,1,3,0)
 ;;=3^Decreased fetal movements, third trimester, fetus 5
 ;;^UTILITY(U,$J,358.3,30270,1,4,0)
 ;;=4^O36.8135
 ;;^UTILITY(U,$J,358.3,30270,2)
 ;;=^5017101
 ;;^UTILITY(U,$J,358.3,30271,0)
 ;;=O43.011^^178^1916^14
 ;;^UTILITY(U,$J,358.3,30271,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30271,1,3,0)
 ;;=3^Fetomaternal placental transfusion syndrome, first trimester
 ;;^UTILITY(U,$J,358.3,30271,1,4,0)
 ;;=4^O43.011
 ;;^UTILITY(U,$J,358.3,30271,2)
 ;;=^5017389
 ;;^UTILITY(U,$J,358.3,30272,0)
 ;;=O43.012^^178^1916^13
 ;;^UTILITY(U,$J,358.3,30272,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30272,1,3,0)
 ;;=3^Fetomaternal placental transfuse syndrome, second trimester
 ;;^UTILITY(U,$J,358.3,30272,1,4,0)
 ;;=4^O43.012
 ;;^UTILITY(U,$J,358.3,30272,2)
 ;;=^5017390
 ;;^UTILITY(U,$J,358.3,30273,0)
 ;;=O43.013^^178^1916^15
 ;;^UTILITY(U,$J,358.3,30273,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30273,1,3,0)
 ;;=3^Fetomaternal placental transfusion syndrome, third trimester
 ;;^UTILITY(U,$J,358.3,30273,1,4,0)
 ;;=4^O43.013
 ;;^UTILITY(U,$J,358.3,30273,2)
 ;;=^5017391
 ;;^UTILITY(U,$J,358.3,30274,0)
 ;;=O36.0110^^178^1916^43
 ;;^UTILITY(U,$J,358.3,30274,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30274,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, first trimester, unsp
 ;;^UTILITY(U,$J,358.3,30274,1,4,0)
 ;;=4^O36.0110
 ;;^UTILITY(U,$J,358.3,30274,2)
 ;;=^5016842
 ;;^UTILITY(U,$J,358.3,30275,0)
 ;;=O36.0111^^178^1916^44
 ;;^UTILITY(U,$J,358.3,30275,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30275,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, first tri, fetus 1
 ;;^UTILITY(U,$J,358.3,30275,1,4,0)
 ;;=4^O36.0111
 ;;^UTILITY(U,$J,358.3,30275,2)
 ;;=^5016843
 ;;^UTILITY(U,$J,358.3,30276,0)
 ;;=O36.0112^^178^1916^45
 ;;^UTILITY(U,$J,358.3,30276,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30276,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, first tri, fetus 2
 ;;^UTILITY(U,$J,358.3,30276,1,4,0)
 ;;=4^O36.0112
 ;;^UTILITY(U,$J,358.3,30276,2)
 ;;=^5016844
 ;;^UTILITY(U,$J,358.3,30277,0)
 ;;=O36.0113^^178^1916^46
 ;;^UTILITY(U,$J,358.3,30277,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30277,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, first tri, fetus 3
 ;;^UTILITY(U,$J,358.3,30277,1,4,0)
 ;;=4^O36.0113
 ;;^UTILITY(U,$J,358.3,30277,2)
 ;;=^5016845
 ;;^UTILITY(U,$J,358.3,30278,0)
 ;;=O36.0114^^178^1916^47
 ;;^UTILITY(U,$J,358.3,30278,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30278,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, first tri, fetus 4
 ;;^UTILITY(U,$J,358.3,30278,1,4,0)
 ;;=4^O36.0114
 ;;^UTILITY(U,$J,358.3,30278,2)
 ;;=^5016846
 ;;^UTILITY(U,$J,358.3,30279,0)
 ;;=O36.0115^^178^1916^48
 ;;^UTILITY(U,$J,358.3,30279,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30279,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, first tri, fetus 5
 ;;^UTILITY(U,$J,358.3,30279,1,4,0)
 ;;=4^O36.0115
 ;;^UTILITY(U,$J,358.3,30279,2)
 ;;=^5016847
 ;;^UTILITY(U,$J,358.3,30280,0)
 ;;=O36.0120^^178^1916^49
 ;;^UTILITY(U,$J,358.3,30280,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30280,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, second trimester, unsp
 ;;
 ;;$END ROU IBDEI1PK
